Key Highlights

  • Stem (NYSE:STEM) fell about 38% and Prenetics about 37% in data covering the November 18, 2026 session, both after third-quarter results.
  • Stem cut its 2026 Revenue guidance to USD 132 million to USD 142 million from USD 140 million to USD 190 million and lowered its year-end ARR target to USD 50 million to USD 55 million.
  • Prenetics beat its revenue guidance with USD 64.1 million, but widened its expected second-half adjusted EBITDA loss to USD 30 million to USD 35 million from USD 8 million to USD 12 million.
  • Stem's results were released on November 16, so part of its decline occurred in earlier sessions; the reported figure may combine more than one day.

Stem Narrows Its Business

Stem (NYSE:STEM) provides software and services for solar and battery storage assets. Its third-quarter results showed revenue of USD 36.7 million, down 4% from a year earlier and below the roughly USD 40.3 million expected. Bookings fell to USD 27.6 million from USD 36.8 million in the second quarter. Profitability improved, with adjusted EBITDA of USD 7.1 million versus USD 2.0 million a year earlier and non-GAAP gross Margin of 58%, up 11 points. Annual Recurring Revenue rose 6% to USD 64.0 million, led by its PowerTrack software, where ARR increased 14% to USD 44.4 million. The company is exiting managed services contracts and battery hardware resale, and agreed to sell its Athena software intellectual property to Voltus for USD 10 million in cash. As a result, it cut 2026 revenue guidance to USD 132 million to USD 142 million and lowered its year-end ARR target to USD 50 million to USD 55 million from USD 65 million to USD 70 million, while raising adjusted EBITDA guidance to USD 15 million to USD 20 million. Cash was USD 36.9 million. The stock fell 12.05% to USD 1.97 in the session after the release and another 20.81% after hours, below its 52-week low.

Prenetics Pays for Growth

Prenetics, which now focuses on its IM8 health supplement brand, reported third-quarter revenue of USD 64.1 million, up 38% from the prior quarter and about 3.3 times the year-earlier level, slightly above its guidance of USD 63 million to USD 64 million. IM8 contributed USD 62.9 million. Gross margin was 64%. The net loss was USD 25.4 million, including a USD 7.2 million non-cash loss on Warrant valuations, and adjusted EBITDA was a loss of USD 12.7 million after Acquisition Marketing of about USD 39.3 million, up from USD 35.7 million in the second quarter. The company reaffirmed fiscal 2026 IM8 revenue of USD 215 million to USD 222 million and targeted at least USD 400 million in 2027. However, it widened its expected second-half adjusted EBITDA loss to USD 30 million to USD 35 million, from USD 8 million to USD 12 million, as it accelerates marketing. Shares fell to about USD 9.39 from USD 16.33. Cash and current financial Assets stood at USD 111.5 million at September 30.

Two Different Resets

The declines share a theme: investors punished companies whose updates pushed profitability or scale further into the future. Stem is shrinking its revenue base to focus on higher-margin software, a strategy that improves margins but reduces the size of the business. The company has also received a stock exchange notice on Market Value and Shareholder Equity and has launched a strategic review, raising questions about its long-term structure. Prenetics is choosing growth over near-term profit, betting that heavy customer acquisition spending will build a large subscription base. The market's reaction suggests scepticism about the payback on that spending. For Stem, the next milestones are the outcome of its strategic review and progress in PowerTrack software. For Prenetics, investors will watch fourth-quarter IM8 revenue, expected at USD 73 million to USD 80 million, and customer acquisition costs.

Where Things Stand

Stem (NYSE:STEM) fell after cutting revenue and ARR guidance as it exits lower-margin businesses, while Prenetics dropped after widening its loss outlook to fund growth. Both now need to show their strategies can deliver profitable scale.